China study isolates and rescues field-derived REV strain

A new paper from China offers a cleaner laboratory foothold on reticuloendotheliosis virus, a poultry pathogen that has been difficult to study in its field form. In a study published October 13, 2026, in Veterinary Sciences, investigators described the isolation, identification, genomic analysis, and rescue of a field-derived REV strain, HB2301, collected from chickens in Hubei Province. The authors position the work as a way around a longstanding problem in REV research: many field samples are tangled up with co-infections or complex genetic backgrounds that limit functional studies. (mdpi.com)

That matters because REV remains a consequential, if sometimes under-recognized, poultry health issue. Merck Veterinary Manual describes reticuloendotheliosis as a neoplastic disease of poultry caused by an avian retrovirus that can produce runting, acute neoplasia, and chronic lymphomas. Although overt outbreaks may be infrequent, surveys suggest the virus is more widespread than once thought, including in chicken and turkey flocks in the US. Older USDA and review literature also note that the biggest economic concerns have included immunosuppression, tumor losses, contamination of live-virus poultry vaccines, and trade implications for breeding stock. (merckvetmanual.com)

According to the study listing, the Hubei birds showed signs including emaciation, depression, and reduced egg production. The authors reported that HB2301 was confirmed as REV-positive by multiplex PCR and immunofluorescence assay, with no detectable avian leukosis virus subgroups A, B, J, or K, or Marek’s disease virus co-infection in the reported testing panel. That distinction is central to the paper’s significance: a field-derived isolate without those detectable confounders can serve as a more interpretable model for studying REV biology than mixed infections often allow. (mdpi.com)

The broader literature helps explain why that cleaner isolate matters. REV infection can suppress immune function, contribute to poor growth, and interfere with vaccination outcomes. A review in Acta Veterinaria Brno notes that REV may lead to vaccination failures and that no effective commercial vaccines are available for REV itself, leaving diagnosis, flock management, and prevention of exposure as key control measures. The same review highlights another longstanding concern for the poultry sector: REV contamination or integration involving fowlpox and Marek’s disease vaccine-related systems has complicated both prevention and interpretation of disease events. (pmc.ncbi.nlm.nih.gov)

I didn’t find a separate institutional press release or outside expert quote tied specifically to the HB2301 paper. Still, the industry perspective in the reference literature is fairly consistent. USDA’s avian disease summaries and Merck’s guidance both frame REV as a pathogen whose clinical impact may be sporadic in the field but whose economic significance is amplified by immunosuppression, diagnostic overlap with other tumor diseases, and biologics safety concerns. In that sense, the new study is less a headline about an outbreak and more a platform-building paper that could support better experimental and surveillance work. (merckvetmanual.com)

Why it matters: For veterinary professionals, especially those in poultry medicine, diagnostic labs, and production health, this study adds a potentially useful reference strain at a time when clean field material is still hard to come by. REV can resemble or coexist with Marek’s disease and avian leukosis, and its immunosuppressive effects can muddy interpretation when flocks underperform or respond poorly to vaccination. A rescued, genomically characterized field isolate could improve reproducibility in challenge studies and help refine assays used in disease surveillance, differential diagnosis, and biologics quality control. That’s particularly relevant because the main control tools for REV remain exclusion, testing, and management rather than vaccination. (mdpi.com)

What to watch: The next question is whether HB2301 becomes a widely used research strain for pathogenicity studies, comparative genomics, and assay validation, and whether future papers show how closely it reflects currently circulating REV in commercial poultry. It will also be worth watching for any follow-up work on transmission dynamics, vaccine-related contamination screening, or comparative virulence against other known REV field isolates. (mdpi.com)